DUBLIN, April 06, 2022–(COMMERCIAL WIRE)–The “US Gene Therapy Market – Industry Outlook and Forecast 2022-2027” Report has been added to ResearchAndMarkets.com offering
The US gene therapy market is expected to grow at a CAGR of 43.44% during 2022-2027. The US gene therapy market would achieve an absolute growth of more than 771.00% in terms of revenue between 2021 and 2027.
In-depth analysis and data-driven insights on the impact of COVID-19 included in this US Gene Therapy Market Report.
The market is experiencing constant growth due to the increased availability of funds from various public and private institutes. In addition, there is increased support from regulatory bodies for product approvals and the provision of fast track designations for products, which encourages suppliers to manufacture products at a faster rate.
SEGMENTATION OF THE US GENE THERAPY MARKET
Among product type segments, the CAR-T therapy segment dominates the US gene therapy market with a 51.96% share, followed by non-CAR-T therapy with 48.04% in 2021.
Based on vector type, the US gene therapy market is segmented into retroviral and others. The other segment includes adenoviruses, adeno-associated viruses, herpes simplex viruses, and non-viral vectors. The retroviral segment represented a majority share of 51.96% and others with 48.04% in 2021
Based on end users, the market is segmented into hospitals, cancer care centers, and academic and research centers. The hospital segment dominated the market with a 56.45% share, followed by cancer care centers with 35.87%.
SELLERS ANALYSIS
The US gene therapy market is seeing intense competition among providers. The market is characterized by the presence of several small-scale and pharmaceutical companies. With the changing market landscape, competition is becoming intense due to some recent high-value mergers and acquisitions.
OPPORTUNITIES AND MARKET TRENDS
-
Increasing market access for gene therapies
-
Introduction of Universal Car-T therapy
-
Increase in strategic acquisitions
-
Increased funding for gene therapy R&D activities
Key Company Profiles
-
Amgen
-
Blue Bird Biography
-
bristol myers squibb
-
Sciences of Gilead
-
Novartis
-
F. Hoffmann-La Roche
Gene therapy research companies
-
4Dmt
-
Abeona Therapeutics
-
angels
-
Question bio
-
Astellas Gene Therapies
-
Autolus therapeutics
-
Therapeutic Candle
-
Castle Creek Biological Sciences
-
Cellectis
-
Evox Therapeutics
-
Free line therapy
-
Gene biotherapy
-
generation biography
-
Gensight Biologics
-
helixsmith
-
Janssen Pharmaceuticals
-
Kolon tissue gene
-
Krystal Biotechnology
-
meiragtx
-
garden therapy
-
Pfizer
-
Poseida Therapeutics
-
organic pass
-
Regenxbio
-
Sana’a Biotechnology
-
Sarepta Therapeutics
-
Stridebio
-
Solid Biosciences
-
Vbl Therapeutics
-
Voyager Therapeutics
-
Unique
Key Topics Covered:
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope and Coverage
4.1 Market definition
4.2 Base year
4.3 Scope of the Study
5 Report assumptions and caveats
5.1 Key Warnings
5.2 Currency conversion
5.3 Market drift
6 Market at a glance
7 Introduction
7.1 Background
7.2 Gene therapy: an overview
8 Reimbursement for gene therapy in the US.
8.1 Summary
9 Regulatory scenario for gene therapy products
9.1 Summary
9.2 Clinical trial process for gene therapy
10 Commercial Gene Therapy Products in the US
10.1 Summary
11 gene therapy products in the works
11.1 Summary
12 market opportunities and trends
12.1 Increased market access for gene therapies
12.2 Introduction of Universal Car-T therapy
12.3 Increase in Strategic Acquisitions
12.4 Increased funding for gene therapy R&D activities
13 market growth enablers
13.1 Augmentation of CMOS to manufacture gene therapies
13.2 Increasing the target patient population
13.3 Product Launches and Regulatory Approvals
13.4 Regulatory support and special designations for gene therapies
14 Market restrictions
14.1 High cost of gene therapy products
14.2 Limitations of gene therapy products
14.3 Availability of Alternative Therapies and Product Recalls
15 Market Overview
15.1 Market Overview
15.2 Market Size and Forecast
15.3 Five Forces Analysis
16 types of vectors
16.1 Market Snapshot and Growth Driver
16.2 Market Overview
16.3 Retrovirals
16.4 Other vectors
17 Product Type
17.1 Market Snapshot and Growth Driver
17.2 Market Overview
17.3 Car-T Therapy
17.4 Therapy without car-T
18 Indication
18.1 Market Snapshot and Growth Driver
18.2 Market Overview
18.3 Oncology
18.4 Others
19 Gene Transfer
19.1 Market Snapshot and Growth Driver
19.2 Market overview
19.3 Ex-Alive
19.4 In vivo
20 end users
20.1 Market Snapshot and Growth Driver
20.2 Market overview
20.3 Hospitals
20.4 Cancer Care Centers
20.5 Academic and Research Centers
21 Competitive Landscape
21.1 Overview of the competition
21.2 Market share analysis
For more information on this report, visit https://www.researchandmarkets.com/r/j4egrk
View the source version on businesswire.com: https://www.businesswire.com/news/home/20220406005780/en/
contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Officer
press@researchandmarkets.com
For business hours EST call 1-917-300-0470
For US/Canada call toll free 1-800-526-8630
For GMT business hours call +353-1-416-8900
